Investing.com - Financial Markets Worldwide

Lanzhou Foci Pharmaceutical Co Ltd (002644)

Shenzhen
Currency in CNY
9.44
0.00(0.00%)
Closed·

002644 Financial Summary

Key Ratios

P/E Ratio73.42
Price/Book2.48
Debt / Equity1.55%
Return on Equity3.49%
Dividend Yield0.13%
EBITDA93.76M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2022
01/01
2023
01/01
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa668.05817.641,042.391,163.13980.23
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa164.42221.07304.16358.96298.76
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa13.2845.6566.162.944.13
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa108.0293.26108.6567.1960.07
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa2,387.182,352.092,606.432,528.12,469.79
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa422.44374.84542.54467.69379.73
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa1,587.11,627.51,741.221,768.431,814.98
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-100.66-41.83-23.7560.54-9.53
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa62.8911.8586.6165.7138.98
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-61.8942.65-42.87-34.16-11.72
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-23.55-93.41-29.06-25-29
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-22.62-39.1115.387.23-1.43
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.12%
Dividend Yield
0.13%
Industry Median 1.51%
Annualised payout
0.01
Paid annually
5-Years Growth
-27.52%
Growth Streak
Unlock

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
0.04 / --
Revenue / Forecast
216.12M / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Lanzhou Foci Pharmaceutical A's earnings for the latest quarter?

The Lanzhou Foci Pharmaceutical A EPS (TTM) is 0.12. Lanzhou Foci Pharmaceutical A reported sales of 216.12, net income of 19.38, and EPS of 0.04 for the latest quarter.

What was Lanzhou Foci Pharmaceutical A's net income for the latest quarter?

Lanzhou Foci Pharmaceutical A's net income for the latest quarter was 19.38.

How did Lanzhou Foci Pharmaceutical A's performance compare year-over-year in the latest quarter?

The company's revenue moved from 271.69 in the previous quarter to 216.12 in the latest quarter, and net income moved from 21.00 to 19.38 compared to the previous quarter.

What is Lanzhou Foci Pharmaceutical A's net profit margin on a TTM basis?

Lanzhou Foci Pharmaceutical A's trailing twelve months (TTM) net profit margin is 6.13%.

How does Lanzhou Foci Pharmaceutical A's debt to equity ratio compare to industry standards?

Lanzhou Foci Pharmaceutical A's total debt-to-equity ratio is 1.55%.

What is Lanzhou Foci Pharmaceutical A's return on investment on a TTM basis?

Lanzhou Foci Pharmaceutical A's trailing twelve months (TTM) return on investment (ROI) is 3.49%.

Did Lanzhou Foci Pharmaceutical A gain or lose cash last quarter?

In the latest quarter, Lanzhou Foci Pharmaceutical A's net change in cash was -11.56 million.

What were Lanzhou Foci Pharmaceutical A's total assets and liabilities in the latest quarter?

As of the latest quarter, Lanzhou Foci Pharmaceutical A reported total assets of 2,420.77 million and total liabilities of 324.79 million.

How has Lanzhou Foci Pharmaceutical A's total revenue grown this year?

Lanzhou Foci Pharmaceutical A's total revenue was 271.69 in the previous quarter and 216.12 in the latest quarter.

What is Lanzhou Foci Pharmaceutical A's gross margin on a TTM basis?

Lanzhou Foci Pharmaceutical A's trailing twelve months (TTM) gross margin is 31.19%.

What was Lanzhou Foci Pharmaceutical A's revenue per share for the latest quarter?

Lanzhou Foci Pharmaceutical A's revenue per share for the latest quarter was 6.97.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.